Physician profile
Amy M Smith
NPI 1821215567
$9,089.40
in general payments reported to CMS, 2019-2025
36 companies · $586 in 2025
The $586 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,086 · 2020: $1,484 · 2021: $1,809 · 2022: $1,978 · 2023: $1,597 · 2024: $550 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,733.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,451.66 | 2021-2025 | Vraylar, Ubrelvy, Synthroid |
| Novo Nordisk INC | $1,301.94 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $966.98 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $679.41 | 2019-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $512.52 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Astellas Pharma US INC | $438.69 | 2020-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $430.52 | 2021-2025 | |
| Glaxosmithkline, LLC. | $384.14 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $346.10 | 2019-2023 | Belsomra, Steglatro |
| Amgen INC. | $309.93 | 2019-2025 | Evenity |
| Kowa Pharmaceuticals America, INC. | $284.68 | 2020-2022 | |
| Allergan, INC. | $283.82 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $263.97 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $162.30 | 2019-2024 | Xarelto |
| Bausch Health US, LLC | $128.09 | 2022-2023 | Aplenzin, Wellbutrin |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.